An ISHLT consensus statement on strategies to prevent and manage hemocompatibility related adverse events in patients with a durable, continuous-flow ventricular assist device.

Life expectancy of patients with a durable, continuous-flow left ventricular assist device (CF-LVAD) continues to increase. Despite significant improvements in the delivery of care for patients with these devices, hemocompatability-related adverse events (HRAEs) are still a concern and contribute to significant morbility and mortality when they occur. As such, dissemination of current best evidence and practices is of critical importance.

On an electromagnetic calculation of ionospheric conductance that seems to override the field line integrated conductivity.

The ionospheric conductance is the major quantity that determines the interaction of the magnetosphere with the ionosphere, where the magnetosphere is the large region of space affected by Earth's geomagnetic field, and the ionosphere is its electrically conducting inner boundary, lying right on the edge of the atmosphere. Storms and substorms in space dissipate their energy through ionospheric currents, which heat the atmosphere and disrupt satellite orbits. The ionospheric conductance has, heretofore, been estimated using the staticized physics known as electrostatic theory, which finds that it can be computed by integrating the zero-frequency conductivity along the lines of Earth's geomagnetic field.

Pembrolizumab-Induced Giant Cell Arteritis in the Setting of Urothelial Carcinoma.

A 65-year-old male presented to the Ophthalmology clinic with painless loss of vision in his right eye. Over the previous week the right eye's vision had progressed from being blurry to complete loss. Three weeks prior to presentation he had begun treatment with pembrolizumab for urothelial carcinoma.

Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinson's Disease.

Background: Unilateral focused ultrasound ablation of the internal segment of globus pallidus has reduced motor symptoms of Parkinson's disease in open-label studies.

Methods: We randomly assigned, in a 3:1 ratio, patients with Parkinson's disease and dyskinesias or motor fluctuations and motor impairment in the off-medication state to undergo either focused ultrasound ablation opposite the most symptomatic side of the body or a sham procedure. The primary outcome was a response at 3 months, defined as a decrease of at least 3 points from baseline either in the score on the Movement Disorders Society-Unified Parkinson's Disease Rating Scale, part III (MDS-UPDRS III), for the treated side in the off-medication state or in the score on the Unified Dyskinesia Rating Scale (UDysRS) in the on-medication state.